Literature DB >> 30136002

Acute Symptomatic Seizures and Provoked Seizures: to Treat or Not to Treat?

Nisali Gunawardane1,2,3, Madeline Fields4,5,6.   

Abstract

PURPOSE OF REVIEW: Acute symptomatic and provoked seizures by definition occur in close proximity to an event and are considered to be situational. The treatment implications and likelihood of recurrence of acute symptomatic and provoked seizures differ from unprovoked seizures. In this article, the authors review the literature on acute symptomatic and provoked seizures with regard to therapeutic approach and risk of recurrence. RECENT
FINDINGS: In the acute period, patients who suffer from acute symptomatic and provoked seizures have higher rates of morbidity and mortality. Patients with acute symptomatic seizures in the setting of certain conditions including subdural hemorrhage, traumatic penetrating injuries, cortical strokes, neurocysticercosis, venous sinus thrombosis, and viral encephalitis have a higher rate of seizure recurrence although the rate of recurrence of seizures is less than that of patients with unprovoked seizures. In patients with acute symptomatic and provoked seizures, short-term treatment with anti-seizure medications is appropriate given the higher morbidity and mortality in the acute phase of illness. In patients with acute symptomatic seizures with persistent epileptiform activity on EEG and structural changes on imaging, longer-term treatment (i.e., a few months as opposed to 1 week) with anti-seizure medications can be considered due to high risk of seizure recurrence. If a patient subsequently has an unprovoked seizure, there is yet a higher risk of recurrence of seizures and likelihood of the development of epilepsy. In these patients, long-term seizure treatment can be considered, keeping in mind that although anti-seizure treatment may reduce risk of seizure recurrence in the short-term, it does not appear to influence long-term seizure remission rates.

Entities:  

Keywords:  Acute symptomatic seizures; Provoked seizures; Remote symptomatic seizures; Unprovoked seizures

Year:  2018        PMID: 30136002     DOI: 10.1007/s11940-018-0525-2

Source DB:  PubMed          Journal:  Curr Treat Options Neurol        ISSN: 1092-8480            Impact factor:   3.598


  52 in total

1.  Evidence-based guideline: Management of an unprovoked first seizure in adults: Report of the Guideline Development Subcommittee of the American Academy of Neurology and the American Epilepsy Society.

Authors:  Allan Krumholz; Samuel Wiebe; Gary S Gronseth; David S Gloss; Ana M Sanchez; Arif A Kabir; Aisha T Liferidge; Justin P Martello; Andres M Kanner; Shlomo Shinnar; Jennifer L Hopp; Jacqueline A French
Journal:  Neurology       Date:  2015-04-21       Impact factor: 9.910

2.  Neurocysticercosis and epilepsy.

Authors:  Jorge G Burneo; Jose E Cavazos
Journal:  Epilepsy Curr       Date:  2014-01       Impact factor: 7.500

3.  Seizures and Epileptiform Discharges in Patients With Acute Subdural Hematoma.

Authors:  Sebastian Pollandt; Bichun Ouyang; Thomas P Bleck; Katharina M Busl
Journal:  J Clin Neurophysiol       Date:  2017-01       Impact factor: 2.177

4.  Immediate versus deferred antiepileptic drug treatment for early epilepsy and single seizures: a randomised controlled trial.

Authors:  A Marson; A Jacoby; A Johnson; L Kim; C Gamble; D Chadwick
Journal:  Lancet       Date:  2005 Jun 11-17       Impact factor: 79.321

5.  Clinical profile and neurodevelopmental outcome of new-onset acute symptomatic seizures in children.

Authors:  Vimlesh Soni; Pratibha Singhi; Arushi Gahlot Saini; Prabhjot Malhi; Radha K Ratho; Baijayantimala Mishra; Sunit C Singhi
Journal:  Seizure       Date:  2017-06-17       Impact factor: 3.184

6.  Risk of recurrent seizures after two unprovoked seizures.

Authors:  W A Hauser; S S Rich; J R Lee; J F Annegers; V E Anderson
Journal:  N Engl J Med       Date:  1998-02-12       Impact factor: 91.245

7.  Continuous electroencephalography in the medical intensive care unit.

Authors:  Mauro Oddo; Emmanuel Carrera; Jan Claassen; Stephan A Mayer; Lawrence J Hirsch
Journal:  Crit Care Med       Date:  2009-06       Impact factor: 7.598

8.  Acute symptomatic seizures in CNS infection.

Authors:  M A Kim; K M Park; S E Kim; M K Oh
Journal:  Eur J Neurol       Date:  2007-11-14       Impact factor: 6.089

9.  Risk of unprovoked seizure after acute symptomatic seizure: effect of status epilepticus.

Authors:  D C Hesdorffer; G Logroscino; G Cascino; J F Annegers; W A Hauser
Journal:  Ann Neurol       Date:  1998-12       Impact factor: 10.422

10.  Risk of post-traumatic epilepsy after severe head injury in patients with at least one seizure.

Authors:  Wei Chen; Ming-De Li; Gui-Fang Wang; Xia-Feng Yang; Lin Liu; Fan-Gang Meng
Journal:  Neuropsychiatr Dis Treat       Date:  2017-08-30       Impact factor: 2.570

View more
  5 in total

Review 1.  Molecular Mechanisms in the Genesis of Seizures and Epilepsy Associated With Viral Infection.

Authors:  Wolfgang Löscher; Charles L Howe
Journal:  Front Mol Neurosci       Date:  2022-05-09       Impact factor: 6.261

2.  Post-acute symptomatic seizure (PASS) clinic: A continuity of care model for patients impacted by continuous EEG monitoring.

Authors:  Vineet Punia; Pradeep Chandan; Jessica Fesler; Christopher R Newey; Stephen Hantus
Journal:  Epilepsia Open       Date:  2020-04-14

Review 3.  Acute symptomatic seizures and status epilepticus in older adults: A narrative review focusing on management and outcomes.

Authors:  Wan Yee Kong; Rohit Marawar
Journal:  Front Neurol       Date:  2022-08-26       Impact factor: 4.086

4.  Association between social deprivation and incidence of first seizures and epilepsy: A prospective population-based cohort.

Authors:  Eimer M Maloney; Paul Corcoran; Daniel J Costello; Éilis J O'Reilly
Journal:  Epilepsia       Date:  2022-06-10       Impact factor: 6.740

Review 5.  The Pharmacology and Clinical Efficacy of Antiseizure Medications: From Bromide Salts to Cenobamate and Beyond.

Authors:  Wolfgang Löscher; Pavel Klein
Journal:  CNS Drugs       Date:  2021-06-18       Impact factor: 5.749

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.